Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
Authors:
- Niamh M. KeeganNKNiamh M. Keegan
- Simon J. FurneySimon J. Furney
- Janice M. WalsheJWJanice M. Walshe
- Giuseppe GulloGGGiuseppe Gullo
- M. John KennedyMKM. John Kennedy
- Diarmuid SmithDSDiarmuid Smith
- John McCaffreyJMJohn McCaffrey
- Catherine M. KellyCKCatherine M. Kelly
- Keith EganKEKeith Egan
- Jennifer KerrJKJennifer Kerr
- Mark GivenMGMark Given
- Peter O’donovanPOPeter O’donovan
Open Access
Abstract
Background: Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted to determine the maximum tolerated dose (MTD) of copanlisib, an intravenous (IV) pan-class I PI3K inhibitor, combined with trastuzumab. Methods: Patients with advanced HER2-positive breast cancer and disease progression following at least one prior line of HER2 therapy in the metastatic setting were treated with copanlisib (45 or 60 mg) IV on days 1, 8 and 15 of a 28-day cycle with a fixed dose of trastuzumab 2 mg/kg weekly. Results: Twelve patients were enrolled. The MTD was determined as copanlisib 60 mg plus trastuzumab 2 mg/kg weekly. The most common adverse events of any grade occurring in more than two patients were hyperglycaemia (58%), fatigue (58%), nausea (58%) and hypertension (50%). Stable disease was confirmed at 16 weeks in six participants (50%). PIK3CA mutations were detected in archival tumour of six participants (50%). PIK3CA hotspot mutations, were detectable in pre- and on-treatment plasma of all participants. Pre- and post-treatment tumour biopsies for two patients identified temporal genomic heterogeneity, somatic mutations in the TRRAP gene, which encodes a PI3K-like protein kinase, and emergent somatic mutations related to protein kinase signalling. Conclusion: Copanlisib and trastuzumab can be safely administered with fair overall tolerability. Preliminary evidence of tumour stability was observed in patients with heavily pre-treated, metastatic HER2 positive breast cancer. Several potential biomarkers were identified for further study in the current phase 2 clinical trial. NCT: 02705859.Keywords
Funding Information
- Health Research Board (ILP-POR-2019-006)
- Irish Cancer Society (CCRC13GAL)
- North East Cancer Research and Education Trust (N/A)
- Fox and Kerins Families (N/A)
This publication has 31 references indexed in Scilit:
- Recent advances in novel targeted therapies for HER2-positive breast cancerAnti-Cancer Drugs, 2012
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Deriving the consequences of genomic variants with the Ensembl API and SNP Effect PredictorBioinformatics, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005